GNPX GENPREX INC

-

GENPREX INC Reported Earnings

Friday, August 14, 2026 · 12:00 AM ET

GENPREX INC (GNPX) reported a loss of $9.40 per share on revenue of $0.00 million for the . .

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small cell lung cancer. Genprex Inc. is based in United States.

Earnings Whisper Grade
Power Rating
Reported Earnings
($9.40)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth-151.3 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth